Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Biotech Acquisition Company Cl A (BIOT)

Biotech Acquisition Company Cl A (BIOT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Astrea Bioseparations to Combine with Biotage AB, Creating Global Chromatography Leader PR Newswire - Wed Feb 15, 2023

/PRNewswire/ -- Gamma Biosciences ("Gamma"), a global life sciences platform formed by KKR to address the advanced therapy market with best-in-class...

KKR : 128.43 (+1.54%)
BIOT : 10.15 (-0.78%)
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment PR Newswire - Wed Jan 4, 2023

/PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in...

BIOT : 10.15 (-0.78%)
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference Business Wire - Mon Aug 1, 2022

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D.,...

BIOT : 10.15 (-0.78%)
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement PR Newswire - Mon Jun 13, 2022

/PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference Business Wire - Wed May 18, 2022

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference Business Wire - Mon May 16, 2022

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package Business Wire - Mon Apr 4, 2022

Blade Therapeutics, Inc. (“Blade” or “Company”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced...

BIOT : 10.15 (-0.78%)
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference Business Wire - Thu Mar 24, 2022

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the company will present...

BIOT : 10.15 (-0.78%)
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis Business Wire - Wed Jan 12, 2022

Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the successful...

BIOT : 10.15 (-0.78%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot